Should I Buy LRMR? LRMR 2026 Analysis

Should You Buy Larimar Therapeutics Inc (LRMR) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

3.570

1 Day change

-2.99%

52 Week Range

5.370

Analysis Updated At

2026/01/26

Larimar Therapeutics Inc (LRMR) is not a strong buy for a beginner investor with a long-term focus and $50,000-$100,000 available. The stock lacks significant positive catalysts, has weak financial performance, and no clear trading signals. It is better to hold off on investing in this stock until more favorable conditions or signals emerge.

Technical Analysis

The MACD histogram is positive at 0.0229, indicating bullish momentum. RSI is at 71.767, which is in the neutral zone but nearing overbought territory. Moving averages are converging, suggesting indecision in the market. The price is trading near the resistance level R1 (3.625) and approaching R2 (3.783), indicating limited upside potential in the short term.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

NULL identified. No recent news or significant insider/hedge fund activity. The stock has a 50% chance of gaining 1.54% in the next week, but this is not a strong enough catalyst for a long-term investment.

Neutral/Negative Catalysts

EPS remains negative at -0.
No recent congress trading data or influential figure activity. The stock's implied volatility is high (112.58), indicating potential risk.

Financial Performance

In Q3 2025, the company reported no revenue growth (0% YoY) and a net income loss of -$47.71M, though this represents a 207.84% YoY improvement. EPS improved to -0.61 (up 154.17% YoY), but the company remains unprofitable. Gross margin remains at 0%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data on analyst ratings or price target changes. Wall Street sentiment appears neutral, with no significant trading trends from hedge funds or insiders.

4 Analyst Rating

Wall Street analysts forecast LRMR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LRMR is 21.5 USD with a low forecast of 21 USD and a high forecast of 22 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 3.680

Low

Averages

21.5

High

Current: 3.680

Low

Averages

21.5

High

Baird

Joel Beatty

Outperform

downgrade

$10 -> $7

AI Analysis

2025-09-30

Reason

Baird

Joel Beatty

Price Target

$10 -> $7

AI Analysis

2025-09-30

downgrade

Outperform

Reason

Baird analyst Joel Beatty lowered the firm's price target on Larimar Therapeutics to $7 from $10 and keeps an Outperform rating on the shares. The firm updated its model to reflect increased safety and regulatory risk following the company's Nomla update.

Citizens JMP

Jonathan Wolleben

Outperform

downgrade

$22 -> $18

2025-08-15

Reason

Citizens JMP

Jonathan Wolleben

Price Target

$22 -> $18

2025-08-15

downgrade

Outperform

Reason

Citizens JMP analyst Jonathan Wolleben lowered the firm's price target on Larimar Therapeutics to $18 from $22 and keeps an Outperform rating on the shares. Larimar will have new open-label data for nomlabofusp in September, which should provide more confidence in the Friedreich's ataxia candidate, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for LRMR

Unlock Now

LRMR Should I Buy

LRMR Should I Buy

Should You Buy Larimar Therapeutics Inc (LRMR) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch